Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

45.83 +1.19 (+2.67%)
Streaming Delayed Price Updated: 11:40 AM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Scholar Rock Holding Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year ↗
Scholar Rock's Phase 3 SAPPHIRE trial for apitegromab in spinal muscular atrophy met its primary endpoint, showing statistically significant motor function improvements and favorable outcomes compared... 
Via Benzinga
News headline image
Pfizer, Vista Outdoor, Duckhorn Portfolio And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
US Stocks Open Lower; Dow Tumbles Over 150 Points ↗
 
Via Benzinga
Topics Stocks
News headline image
Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy ↗
The company is hoping to treat patients with spinal muscular atrophy, a muscle-wasting disease. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)
From Scholar Rock
Via Business Wire
News headline image
Constellation Energy, Nike, Sinclair And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Participate in Upcoming Investor Conferences
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
SRRK Stock Earnings: Scholar Rock Holding Beats EPS for Q2 2024 ↗
SRRK stock results show that Scholar Rock Holding beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Participate in Upcoming Investor Conferences
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Host Investor Day on May 22, 2024
From Scholar Rock
Via Business Wire
News headline image
SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q1 2024 ↗
SRRK stock results show that Scholar Rock Holding missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
News headline image
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains ↗
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly. 
Via InvestorPlace
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Is A Potential M&A Target, Its Exploration of Obesity Market Garners Interest: Analyst ↗
Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK), supported by the potential value with a couple of key programs utilizing selective myostatin inhibition to  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.